May 7 |
The 3 Best Nasdaq Stocks to Buy in May 2024
|
May 7 |
Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges
|
May 7 |
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
|
May 7 |
Rhythm Pharmaceuticals GAAP EPS of -$2.35 misses by $0.33, revenue of $25.97M misses by $0.93M
|
May 7 |
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
|
May 6 |
Rhythm Pharmaceuticals Q1 2024 Earnings Preview
|
May 6 |
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
|
May 1 |
Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
|
Apr 30 |
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
|
Apr 29 |
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
|